ArticleFrontiers in oncology2025
Clinical practice of early screening and risk-stratified management for oral potentially malignant disorders.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Beyond Clinicopathological Criteria: A Practical Management Framework for Oral Lichen Planus.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Article
- Diagnostic treatment modalities premalignant oral lesions oral cancer progression impact: Comparative study.Bioinformation · 2026Article
- A spatial-microbial-metabolic-immune framework for high-risk oral potentially malignant disorders: an evidence-ranked review for malignant transformation risk stratification.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the application value of standardized screening and risk-stratified management in the clinical practice of Oral Potentially Malignant Disorders (OPMDs) for improving early diagnosis rates and optimizing intervention strategies. Methods: A total of 312 OPMD patients diagnosed between January 2017 and December 2022 were enrolled. A screening pathway of "initial screening (questionnaire + visual/tactile examination) - refined screening (pathological biopsy)" was established. Risk stratification (low, intermediate, high) was performed using a modified Proliferative Verrucous Leukoplakia (PVL)-based scoring system. Multidisciplinary team (MDT) management was implemented. Risk factors for malignant transformation were analyzed using Cox regression. Results: The high-risk group had a significantly higher malignant transformation rate than the intermediate and low-risk groups (12.5% vs. 3.5% vs. 0%, P<0.001), with a shorter median time to transformation (23.4 months). Severe epithelial dysplasia (HR = 6.24), lesions located in the tongue ventral/floor of mouth (HR = 3.34), and betel quid chewing history (HR = 2.62) were identified as independent risk factors. The MDT model achieved a 2-year cancer-free survival rate of 91.4% in high-risk patients and improved follow-up compliance to 83.3%. Conclusion: An OPMD management model based on risk stratification and MDT collaboration can effectively identify high-risk patients, optimize intervention timing, and improve prognosis. This model is suitable for promotion in primary care hospitals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.